We inform all respected laboratories that ANSHLAB American Company has started designing and selling all kits regarding antenatal screening including AFP,BHCG,VE3,INHIBIN,and PAPP-A.
These products have CE and FDA and high accuracy and sensivity.
For more information about how to sell and sign orders, please call Nano Mehr assistance.
...
|
|
In order to check the results for mothers having different positive screening results, a system called outcome is designed .In this part, Alpha provides you with the data on all your patients.
In this part of your application, you must record data related to the results ofamino synthesis and the presence and absence of congenital defects after baby`s birth. This quality causes you control the the performance results of screening pregnant mothers.
With using outcome you can have data on pregnant mothers with children having different abnormalities, in a list.
This system provides you with a list that show the results of pregnant mothers who their results have not prepared yet with the data in which the screening will be done. And the baby will be born.
What makes this system so laboratories can screen your application performance over a period of review is comparison with real cases having abnormalities and obtained results in the software.
You can also obtain the real am ...
|
|
Nowadays, reflex DNA screen in Alpha prenatal software runs screening protocol whit using DNA parts in the plasma of mothers.
The benefit of this test is a low price in comparison with public DNA test and low amount of false positive cases of this test. In REFLEX DNASCREEN, mothers should first be screened by the tests of the first, second or third quarter.
In the event that pregnant mothers recognizes in a high-risk group, a cell free DNA test will automatically introduce to do the test.
Different Cut offs have determined to do the test for different Trisomy.
In the design of this protocol, different cases have considered that will be announced later.
...
|
|
The calculation of the risk of preeclampsia in Alpha is done by AFP-UE3-HCG and INHIBIN A+PLGF in the second quarter PLGF-PAPP-A and the average of arteriolar pressure is used for the calculation of the risk in the first quarter.
This allows an opportunity for grater oversight of this anomaly and will help in the prophylactic treatment of patients who have a high risk.
By using markers in Quad + PLGF test, the estimate of the risk of preeclampsia,52% detection rate and false positive rate of 5% can be created. If you are using PAPP-A and MAP in the first quarter and adding markers in Quad + PLGF marker in the second trimester, the detection rate to detect the abnormality will be 64%.
...
|
|
Scientific advances:
αlpha 8 can be used for Down’s syndrome screening using first trimester placental growth factor as a marker 88. This marker was previously not available in αlpha.
αlpha 8 includes the latest statistical parameters for pre-eclampsia screening. Pre-eclampsia screening using first trimester PAPP-A, mean arterial pressure (MAP) and first and second trimester placental growth factor 89, 93, 94 is now possible. These markers were not previously available for pre-eclampsia screening.
αlpha 8 can calculate screening performance estimates for Down’s syndrome, trisomy 18, SLOS, trisomy 13 and pre-eclampsia. Previously screening performance estimates for Down’s syndrome only could be calculated. Since version 8.0.14120.22 the detection rate at a fixed false positive rate and the false positive rate for a fixed detection rate are both calculated.
αlpha 8 includes a gestation specific adjustment for inhibin-A for ...
|
|
|
Archive News
